MoonLake Reports Week 52 Phase 3 Data for Hidradenitis Suppurativa Drug Candidate
MoonLake announced on Monday, June 22, 2026, the Week 52 results from its Phase 3 VELA program, which is evaluating the drug candidate sonelokimab for the treatment of hidradenitis suppurativa (HS). The data, released by the biotechnology company, offers a comprehensive look at the drug’s performance over a full year of treatment. Financial and healthcare […]